Nexsen’s FlashDx partnership opens a second route into GBS diagnostics

• 50:50 non-binding JV with FlashDx Shenzhen
• Existing CE-marked molecular GBS test provides the technical base
• Nexsen to fund and lead planned FDA 510(k) and CE-IVDR pathways
• Separate hospital and intrapartum product alongside StrepSure
• Trading suspension lifted following the JV announcement

FlashDx platform gives Nexsen a faster starting point

Nexsen Limited (ASX:NXN) is proposing a 50:50 joint venture with FlashDx Shenzhen Inc. to develop and commercialise an enhanced molecular test for Group B Streptococcus, giving the ASX-listed diagnostics company access to an established CE-marked product rather than requiring it to build a molecular system from scratch.

FlashDx would contribute its molecular technology, manufacturing capability and associated know-how. Nexsen would bring a sample-preparation enhancement intended to release more GBS material from vaginal swab samples, helping the test detect low bacterial levels, and would fund and lead the agreed regulatory programme. The existing FlashDx test is a fully automated real-time PCR system that produces results in under an hour, according to the announcement.

Two GBS products aimed at different clinical settings

The proposed product is intended for hospital and intrapartum testing, placing it in a different clinical setting from Nexsen’s StrepSure programme. StrepSure is being developed as a rapid lateral-flow test for antenatal screening and decentralised care, while the FlashDx venture would pursue a molecular testing pathway closer to delivery. Nexsen says the products are intended to address different workflows, applications and price points rather than compete for the same use case.

The distinction matters because GBS colonisation can change during pregnancy. Current screening is typically performed at 36 to 37 weeks, while a rapid test during labour could provide a more immediate indication of a woman’s GBS status. The company cites around 132 million births globally each year and estimates that GBS is carried by 10% to 30% of pregnant women, although those figures describe the broader disease and testing opportunity rather than a forecast for Nexsen’s products.

Nexsen targets Hong Kong, India and regulatory expansion

Nexsen expects Hong Kong to be an initial focus for the venture, with India also identified as a significant target market subject to local regulatory requirements. The company says its existing clinical and commercial relationships across Asia-Pacific could support market entry, including research facilities in Hong Kong and through Universiti Malaya, as well as a hospital partnership in Hong Kong.

The parties intend to pursue US Food and Drug Administration 510(k) clearance and conformity under Europe’s CE-IVDR regime. Three US clinical sites already engaged by Nexsen are intended to support the US programme, while FlashDx would provide the testing platform and clinical trial materials. No regulatory timetable, transaction value or detailed funding amount was disclosed.

Non-binding terms leave execution risk unresolved

The proposed structure would see the new venture owned equally by Nexsen and FlashDx, with profits shared equally. FlashDx would exclusively manufacture and supply the test, while the venture would hold regulatory data, submissions and future intellectual property developed for the product. FlashDx would transfer relevant cartridge-specific intellectual property after the targeted regulatory approvals, while retaining ownership of its broader platform, reader, manufacturing know-how and other background intellectual property.

Those arrangements remain proposals rather than completed commitments. The term sheet is non-binding and the venture still requires a detailed business plan, binding shareholder, manufacturing, supply, marketing and distribution agreements, product development and regulatory clearance. ASX has said Nexsen’s trading suspension will be lifted immediately following the announcement, putting the proposed deal back in front of the market before any of those milestones has been secured.

Bottom Line?

The venture gives Nexsen a more advanced molecular starting point, but the investment case now turns on binding documentation, regulatory execution and evidence that the two-product GBS strategy can reach commercial markets.

Questions in the middle?

• When will Nexsen and FlashDx complete binding joint venture and supply agreements?
• What regulatory timetable and funding commitment will be required for FDA 510(k) and CE-IVDR submissions?
• Can the enhanced product demonstrate sufficient performance and pricing advantages to gain hospital adoption in Asia-Pacific?